Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection
Not yet recruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
February 1, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Conditions
Immune Dysregulation Disorder
Interventions
DRUG
Eravacycline
There is no other intervention.
All Listed Sponsors
lead
Sichuan Provincial People's Hospital
OTHER
NCT06223100 - Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection | Biotech Hunter | Biotech Hunter